How Does Gilead Sciences Make its Money?
Gilead Sciences is a biopharmaceutical company best known for its dominance in HIV treatment and its antiviral therapies. The company’s Biktarvy has become the most prescribed HIV treatment in the world, while Veklury (remdesivir) gained prominence during the COVID-19 pandemic. Gilead has been diversifying into oncology through its acquisition of Kite Pharma (CAR-T cell therapy) and Immunomedics (Trodelvy for cancer). The company aims to build a portfolio beyond virology to drive long-term growth.
Gilead Sciences (GILD) Business Model
Gilead Sciences operates in the biotechnology sector. Below is a summary of Gilead Sciences’ revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from Gilead Sciences’ 2024 fiscal year filings with the SEC.
Gilead Sciences Competitors
Gilead Sciences’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Pfizer, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Gilead Sciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Gilead Sciences Competitors
Gilead Sciences’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Pfizer, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Gilead Sciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Gilead Sciences Competitors
Gilead Sciences’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Pfizer, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Gilead Sciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Gilead Sciences Competitors
Gilead Sciences’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Pfizer, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Gilead Sciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Gilead Sciences Competitors
Gilead Sciences’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Pfizer, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Gilead Sciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Gilead Sciences Competitors
Gilead Sciences’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Pfizer, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Gilead Sciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Gilead Sciences Competitors
Gilead Sciences’s key competitors and comparable public companies in the biotechnology sector include Amgen, Eli Lilly, Pfizer, and Moderna. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Gilead Sciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Biktarvy (HIV) | $13,500 | $12,100 | +11.6% |
| Other HIV Products | $3,700 | $4,100 | -9.8% |
| Veklury (COVID-19) | $1,400 | $1,900 | -26.3% |
| Oncology (Trodelvy, Yescarta, Tecartus) | $3,200 | $2,600 | +23.1% |
| Liver Disease (Vemlidy, etc.) | $2,800 | $2,700 | +3.7% |
| Other Products | $3,200 | $2,700 | +18.5% |
| Total Revenue | $28,300 | $27,100 | +4.4% |
Biktarvy (HIV) — 48% of Revenue
Other HIV Products — 13% of Revenue
Veklury (COVID-19) — 5% of Revenue
Oncology (Trodelvy, Yescarta, Tecartus) — 11% of Revenue
Liver Disease (Vemlidy, etc.) — 10% of Revenue
Other Products — 11% of Revenue
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $28,300 | $27,100 |
| Cost of Revenue | $8,000 | $7,600 |
| Gross Profit | $20,300 | $19,500 |
| Operating Expenses | $11,400 | $12,500 |
| Operating Income | $8,900 | $7,000 |
| Net Income | $6,400 | $5,500 |
All values in millions USD unless otherwise stated.
Key Financial Metrics
- Gross Margin: 71.7%
- Operating Margin: 31.4%
- Revenue Growth: 4.4%
Is Gilead Sciences Profitable?
Yes, Gilead Sciences is profitable. The company reported net income of $6,400 on total revenue of $28,300. With an operating margin of 31.4%, Gilead Sciences demonstrates solid profitability for the biotechnology sector. The gross margin of 71.7% reflects Gilead Sciences’ pricing power and cost structure.
What to Watch
- Long-acting HIV drug lenacapavir (Sunlenca) adoption and PrEP approval progress
- Oncology pipeline growth through Kite’s CAR-T therapies and Trodelvy expansion
- Veklury revenue trajectory as COVID treatment demand normalizes
- Capital allocation between dividends, buybacks, and M&A for pipeline expansion
Gilead Sciences (GILD) Financial Summary
Gilead Sciences (GILD) is a biotechnology company that generated $28,300 in total revenue in fiscal year 2024. Revenue grew 4.4% year-over-year. The company earned $6,400 in net income, making it profitable. For a deeper look at Gilead Sciences’ revenue breakdown, business segments, and financial performance, review the detailed analysis above.